Literature DB >> 12397465

Early changes in [18F]FLT uptake after chemotherapy: an experimental study.

Helmut Dittmann1, Bernhard Matthias Dohmen, Rainer Kehlbach, Gabi Bartusek, Maren Pritzkow, Mario Sarbia, Roland Bares.   

Abstract

This study evaluated the use of 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) for monitoring of the early effects of anticancer chemotherapy on tumour cell proliferation. Cells derived from human oesophageal squamous cell carcinoma (OSC-1) were grown for 2 days and incubated with cisplatin (CDDP), 5-fluorouracil (5-FU), methotrexate (MTX) or gemcitabine (GEM) for 4 h. Cultures were incubated with drug doses (CDDP: 0.67, 6.7, 67 micro M; 5-FU 15.4, 154, 1,540 micro M; MTX: 4.4, 44, 440 micro M; GEM: 0.0067, 0.067, 0.67 micro M) corresponding to approximately 10%-95% proliferation inhibition (MTX: 10%-75%). Treatment was stopped and cells were allowed to recover for 4, 24 or 72 h. [(18)F]FLT was added for 10-180 min. Control cultures were incubated with [(18)F]fluorodeoxyglucose (FDG). Cell counts, viability, clonogenic activity and cell cycle distribution estimated by flow cytometry were used to evaluate the cytotoxic effects of chemotherapy. Strikingly, FLT uptake per 10(5) viable cells was increased seven- to tenfold 24 h after treatment with 5-FU or MTX irrespective of dose. Thus, total FLT uptake per tissue culture exceeded that of controls despite a considerable decrease in overall cell counts due to cytostasis up to 72 h after treatment. 5-FU-treated cells showed accumulation in early S phase (overall S phase: 88% vs 42%). GEM treatment resulted in a more moderate increase in total FLT accumulation, to a maximum of fivefold at the dose close to the IC(50). In contrast, FLT accumulation was significantly reduced at cytostatic concentrations of CDDP and was still decreasing in a dose-related manner at 72 h despite considerable S phase arrest. With 5-FU or CDDP, the uptake of FDG did not differ significantly from control values 24 h after treatment. These findings demonstrate that tumour cell uptake of FLT - in contrast to that of FDG - reveals specific changes depending on the cytostatic drug used for treatment. The antimetabolites 5-FU and MTX massively increase FLT accumulation per cell independent of dose, i.e. cytotoxicity. Early after treatment, this increase is not predictive of proliferation inhibition but reflects activated salvage pathway of DNA synthesis. By contrast, CDDP results in an early decline in FLT but not in FDG uptake. This drug-specific modulation of FLT uptake has to be taken into account in positron emission tomography studies using FLT for treatment monitoring.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397465     DOI: 10.1007/s00259-002-0925-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  44 in total

1.  Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

Authors:  Sarah R Mudd; Kimberley D Holich; Martin J Voorbach; Todd B Cole; David R Reuter; Paul Tapang; Gail Bukofzer; Arunava Chakravartty; Cherrie K Donawho; Joann P Palma; Gerard B Fox; Mark Day; Yanping Luo
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

Review 2.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 3.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

4.  Early response assessment in prostate carcinoma by ¹⁸F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models.

Authors:  Nobuyuki Oyama; Yoko Hasegawa; Yasushi Kiyono; Masato Kobayashi; Yasuhisa Fujibayashi; Datta E Ponde; Carmen Dence; Michael J Welch; Osamu Yokoyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-29       Impact factor: 9.236

5.  Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

Authors:  Sven N Reske; Sandra Deisenhofer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

6.  Assessment of therapy response in malignant tumours with 18F-fluorothymidine.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

7.  FLT-PET imaging of radiation responses in murine tumors.

Authors:  M H Pan; S C Huang; Y P Liao; D Schaue; C C Wang; D B Stout; J R Barrio; W H McBride
Journal:  Mol Imaging Biol       Date:  2008-08-01       Impact factor: 3.488

8.  [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.

Authors:  Seung Jin Choi; Jae Seung Kim; Jeong Hoon Kim; Seung Jun Oh; Jeong Gyo Lee; Chang Jin Kim; Young Shin Ra; Jeong Seok Yeo; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-15       Impact factor: 9.236

Review 9.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

10.  Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

Authors:  David M Atkinson; Michelle J Clarke; Ann C Mladek; Brett L Carlson; David P Trump; Mark S Jacobson; Brad J Kemp; Val J Lowe; Jann N Sarkaria
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.